Ⅴ. 行政施策への貢献の可能性

(1)B型肝炎患者は病気の「完治」を希望しているが，HBVの性質上，感染成立後は完全に排除できないため，ウイルスの増殖を抑制することが現状では限界である．しかしながら，細胞核内のHBVDNAを不活化する可能性がある本研究を進めることで，患者の望む完治に極めて近い治療を提供できると考えられる．
(2)本研究で開発を行うDDSは，肝臓特異的に輸送できるナノデバイスの完成を目指しており，他にも様々な応用が可能なため，既存または将来開発される薬剤の輸送手段を改善でき，汎用性がある．
(3)近年知られているHBV再活性化は，免疫抑制を伴う移植や分子標的治療でそのリスクが増大している．HBVの不活化が出来れば，この問題に対しても解決策となるものである．

Ⅵ. 本研究の成果(発表論文・ガイドライン・マニュアル等)

研究代表者

(1)Sunbul M, Sugiyama M, Kurbanov F, Leblebicioglu H, Khan A, Elkady A, Tanaka Y, and Mizokami M. Specific mutations of basal core promoter are associated with chronic liver disease in hepatitis B virus subgenotype D1 prevalent in Turkey. *Microbiol Immunol.* 2012 in press

研究分担者（片岡　一則）

(2) Gouda N, Miyata K, Christie RJ, Suma T, Kishimura A, Fukushima S, Nomoto T, Liu X, Nishiyama N, Kataoka K. Silica nanogelling of environment-responsive PEGylated polyplexes for enhanced stability and intracellular delivery of siRNA. *Biomaterials.* 2013 Jan;34(2):562-70.
(3)Sanjoh M, Miyata K, Christie RJ, Ishii T, Maeda Y, Pittella F, Hiki S, Nishiyama N, Kataoka K. Dual environment-responsive polyplex carriers for enhanced intracellular delivery of plasmid DNA. *Biomacromolecules.* 2012 Nov 12;13(11):3641-9.

研究分担者（中西　真）

(4)Liu N, Matsumoto M, Kitagawa K, Kotake Y, Suzuki S, Shirasawa S, Nakayama KI, Nakanishi M, Niida H, Kitagawa M. Chk1 phosphorylates the tumor suppressor Mig-6, regulating the activation of EGF signaling. *EMBO J.* 2012 in press

研究分担者（武冨　紹信）

(5)Takeishi K, Taketomi A, Shirabe K, Toshima T, Motomura T, Ikegami T, Yoshizumi T, Sakane F, Maehara Y. Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway. *J Hepatol*, 2012 Jul;57(1):77-83.
(6)Takeishi K, Taketomi A, Shirabe K, Toshima T, Motomura T, Ikegami T, Yoshizumi T, Sakane F, Maehara Y. Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway. *J Hepatol*, 2012 Jul;57(1):77-83.

研究分担者（田中　榮司）

(7)Matsumoto A, Tanaka E, Morita S, Yoshizawa K, Umemura T, Joshita S. Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection. *J Gastroenterol* 2012;47(9):1006-1013

研究分担者（星野　真一）

(8)Ogami, K., Hosoda, N., Funakoshi, N., Hoshino, S. Anti prolifetative protein Tob directly regulates c-myc proto-oncogene expression through cytoplasmic polyadenylation element-binding protein CPEB. *Oncogene* 2012 in press
(9)Osawa, M., Hosoda, N., Nakanishi, T., Uchida, N., Kimura, T., Imai, S., Machiyama, A., Katada, T., Hoshino, S., Shimada, I. Biological role of the two overlapping poly(A)-binding protein interacting motifs 2 (PAM2) of eukaryotic releasing factor eRF3 in mRNA decay. *RNA* 2012 18, 1957-1967.

研究分担者（杉山　真也）

(10)Sunbul M, Sugiyama M, Kurbanov F, Leblebicioglu H, Khan A, Elkady A, Tanaka Y, and Mizokami M. Specific mutations of basal core promoter are associated with chronic liver disease in hepatitis B virus subgenotype D1 prevalent in Turkey. *Microbiol Immunol.* 2012 in press

Ⅶ. Ⅲ（1 年間の研究成果）の概要図等

※ポンチ絵等でわかりやすく簡潔に説明してください。



●研究代表者の研究歴等

※研究代表者に関するもののみを記載してください。（研究代表者には下線をつけて下さい）

・過去に所属した研究機関の履歴

昭和51年4月　名古屋市立大学医学部　第二内科
平成元年11月　King`s College Hospital, Liver Unit
平成10年7月　名古屋市立大学　輸血部
平成12年11月　名古屋市立大学　臨床検査医学
平成13年11月　名古屋市立大学大学院医学研究科　臨床分子情報医学分野
平成20年10月　国立国際医療センター国府台病院　肝炎・免疫研究センター
平成22年4月　独立行政法人国立国際医療研究センター　肝炎・免疫研究センター

・主な共同研究者（又は指導を受けた研究者）

五條堀孝（国立遺伝学研究所）、脇田隆字（国立感染症研究所）、徳永勝士（東京大学）
田中靖人（名古屋市立大学）、Williams R. (King's College Hospital, Liver Unit)、Alter HA.(NIH)

・主な研究課題

ウイルス肝炎の病態と治療に関わるウイルス・宿主因子の解析とその応用による新規治療法・検査法の開発

・これまでの研究実績

※研究代表者の本研究の成果以外の実績も記載してください。
（成果概要Ⅵと重複するものや本研究成果によるものは、***太字・斜体***文字で記載してください）
※発表論文名・学協会誌名・発表年（西暦）、知的財産権の取得及び申請状況、研究課題の実施を通じた政策提言（寄与した指針又はガイドライン等）のうち、主なものを選択し、直近年度から順に記載してください。

原著論文

1. ***Sunbul M, Sugiyama M, Kurbanov F, Leblebicioglu H, Khan A, Elkady A, Tanaka Y, and Mizokami M. Specific mutations of basal core promoter are associated with chronic liver disease in hepatitis B virus subgenotype D1 prevalent in Turkey. Microbiol Immunol. 2012 in press***
2. Yoshio S, Kanto T, Kuroda S, Matsubara T, Higashitani K, Kakita N, Ishida H, Hiramatsu N, Nagano H, Sugiyama M, Murata K, Fukuhara T, Matsuura Y, Hayashi N, Mizokami M, Takehara T. Human BDCA3(+) dendritic cells are a potent producer of IFN-λ in response to hepatitis C virus. *Hepatology*. 2012 Dec 5. in press
3. Watanabe T, Sugauchi F, Tanaka Y, Matsuura K, Yatsuhashi H, Murakami S, Iijima S, Iio E, Sugiyama M, Shimada T, Kakuni M, Kohara M, Mizokami M. Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. *Gut*. 2012 Nov 7. in press
4. Kumar V, Yi Lo PH, Sawai H, Kato N, Takahashi A, Deng Z, Urabe Y, Mbarek H, Tokunaga K, Tanaka Y, Sugiyama M, Mizokami M, Muroyama R, Tateishi R, Omata M, Koike K, Tanikawa C, Kamatani N, Kubo M, Nakamura Y, Matsuda K. Soluble MICA and a MICA variation as possible prognostic

biomarkers for HBV-induced hepatocellular carcinoma. *PLoS One*. 2012;7(9):e44743.

5. Nakamura M, Nishida N, Kawashima M, Aiba Y, Tanaka A, Yasunami M, Nakamura H, Komori A, Nakamuta M, Zeniya M, Hashimoto E, Ohira H, Yamamoto K, Onji M, Kaneko S, Honda M, Yamagiwa S, Nakao K, Ichida T, Takikawa H, Seike M, Umemura T, Ueno Y, Sakisaka S, Kikuchi K, Ebinuma H, Yamashiki N, Tamura S, Sugawara Y, Mori A, Yagi S, Shirabe K, Taketomi A, Arai K, Monoe K, Ichikawa T, Taniai M, Miyake Y, Kumagi T, Abe M, Yoshizawa K, Joshita S, Shimoda S, Honda K, Takahashi H, Hirano K, Takeyama Y, Harada K, Migita K, Ito M, Yatsuhashi H, Fukushima N, Ota H, Komatsu T, Saoshiro T, Ishida J, Kouno H, Kouno H, Yagura M, Kobayashi M, Muro T, Masaki N, Hirata K, Watanabe Y, Nakamura Y, Shimada M, Hirashima N, Komeda T, Sugi K, Koga M, Ario K, Takesaki E, Maehara Y, Uemoto S, Kokudo N, Tsubouchi H, Mizokami M, Nakanuma Y, Tokunaga K, Ishibashi H. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. *Am J Hum Genet*. 2012 Oct 5;91(4):721-8.
6. Date T, Kato T, Kato J, Takahashi H, Morikawa K, Akazawa D, Murayama A, Tanaka-Kaneko K, Sata T, Tanaka Y, Mizokami M, Wakita T. Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone. *J Virol*. 2012 Oct;86(19):10805-20.
7. ○Nishida N, Sawai H, Matsuura K, Sugiyama M, Ahn SH, Park JY, Hige S, Kang JH, Suzuki K, Kurosaki M, Asahina Y, Mochida S, Watanabe M, Tanaka E, Honda M, Kaneko S, Orito E, Itoh Y, Mita E, Tamori A, Murawaki Y, Hiasa Y, Sakaida I, Korenaga M, Hino K, Ide T, Kawashima M, Mawatari Y, Sageshima M, Ogasawara Y, Koike A, Izumi N, Han KH, Tanaka Y, Tokunaga K, Mizokami M. Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. *PLoS One*. 2012;7(6):e39175.
8. ○Sawai H, Nishida N, Mbarek H, Matsuda K, Mawatari Y, Yamaoka M, Hige S, Kang JH, Abe K, Mochida S, Watanabe M, Kurosaki M, Asahina Y, Izumi N, Honda M, Kaneko S, Tanaka E, Matsuura K, Itoh Y, Mita E, Korenaga M, Hino K, Murawaki Y, Hiasa Y, Ide T, Ito K, Sugiyama M, Ahn SH, Han KH, Park JY, Yuen MF, Nakamura Y, Tanaka Y, Mizokami M, Tokunaga K. No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. *BMC Med Genet*. 2012 Jun 19;13:47.
9. ○Michikawa T, Inoue M, Sawada N, Iwasaki M, Tanaka Y, Shimazu T, Sasazuki S, Yamaji T, Mizokami M, Tsugane S; Japan Public Health Center-based Prospective Study Group. Development of a prediction model for 10-year risk of hepatocellular carcinoma in middle-aged Japanese: the Japan Public Health Center-based Prospective Study Cohort II. *Prev Med*. 2012 Aug;55(2):137-43.
10. ○Zhou B, Wang Z, Yang J, Sun J, Li H, Tanaka Y, Mizokami M, Hou J. Novel evidence of HBV recombination in family cluster infections in western China. *PLoS One*. 2012;7(6):e38241.
11. Sugiyama M, Kimura T, Naito S, Mukaide M, Shinauchi T, Ueno M, Ito K, Murata K, Mizokami M. Development of specific and quantitative real-time detection PCR and immunoassays for λ3-interferon. *Hepatol Res*. 2012 Nov;42(11):1089-99.
12. Nomura H, Miyagi Y, Tanimoto H, Yamashita N, Ito K, Masaki N, Mizokami M. Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination

therapy. *J Gastroenterol Hepatol.* 2012 Sep;27(9):1461-6.

13. Kani S, Tanaka Y, Matsuura K, Watanabe T, Yatsuhashi H, Orito E, Inose K, Motojuku N, Wakimoto Y, Mizokami M. Development of new IL28B genotyping method using Invader Plus assay. *Microbiol Immunol.* 2012 May;56(5):318-23.
14. Saito H, Ito K, Sugiyama M, Matsui T, Aoki Y, Imamura M, Murata K, Masaki N, Nomura H, Adachi H, Hige S, Enomoto N, Sakamoto N, Kurosaki M, Mizokami M, Watanabe S. Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients. *Hepatol Res.* 2012 Oct;42(10):958-965.
15. ○Ito K, Kuno A, Ikehara Y, Sugiyama M, Saito H, Aoki Y, Matsui T, Imamura M, Korenaga M, Murata K, Masaki N, Tanaka Y, Hige S, Izumi N, Kurosaki M, Nishiguchi S, Sakamoto M, Kage M, Narimatsu H, Mizokami M. LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. *Hepatology.* 2012 Oct;56(4):1448-56.
16. ○Sawada N, Inoue M, Iwasaki M, Sasazuki S, Shimazu T, Yamaji T, Takachi R, Tanaka Y, Mizokami M, Tsugane S; Japan Public Health Center-Based Prospective Study Group. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. *Gastroenterology.* 2012 Jun;142(7):1468-75.
17. ○Ragheb M, Elkady A, Tanaka Y, Murakami S, Attia FM, Hassan AA, Hassan MF, Shedid MM, Abdel Reheem HB, Khan A, Mizokami M. Multiple intra-familial transmission patterns of hepatitis B virus genotype D in north-eastern Egypt. *J Med Virol.* 2012 Apr;84(4):587-95.
18. Date T, Morikawa K, Tanaka Y, Tanaka-Kaneko K, Sata T, Mizokami M, Wakita T. Replication and infectivity of a novel genotype 1b hepatitis C virus clone. *Microbiol Immunol.* 2012 May;56(5):308-17.
19. Mizokami M. Discovery of critical host factor, IL-28B, associated with response to hepatitis C virus treatment. *J Gastroenterol Hepatol.* 2012 Mar;27(3):425-9.
20. Murayama A, Kato T, Akazawa D, Sugiyama N, Date T, Masaki T, Nakamoto S, Tanaka Y, Mizokami M, Yokosuka O, Nomoto A, Wakita T. Production of infectious chimeric hepatitis C virus genotype 2b harboring minimal regions of JFH-1. *J Virol.* 2012 Feb;86(4):2143-52.
21. Nakano T, Lau GM, Lau GM, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. *Liver Int.* 2012 Feb;32(2):339-45.
22. Raghwani J, Thomas XV, Koekkoek SM, Schinkel J, Molenkamp R, van de Laar TJ, Takebe Y, Tanaka Y, Mizokami M, Rambaut A, Pybus OG. Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1b. *J Virol.* 2012 Feb;86(4):2212-20.
23. ○Mumtaz K, Hamid S, Ahmed S, Moatter T, Mushtaq S, Khan A, Mizokami M, Jafri W. A study of genotypes, mutants and nucleotide sequence of hepatitis B virus in Pakistan: HBV genotypes in pakistan. *Hepat Mon.* 2011 Jan;11(1):14-8.
24. ○Sugiyama M, Inui A, Shin-I T, Komatsu H, Mukaide M, Masaki N, Murata K, Ito K, Nakanishi M, Fujisawa T, Mizokami M. Easy-to-use phylogenetic analysis system for hepatitis B virus infection. *Hepatol Res.* 2011 Oct;41(10):936-45.
25. ○ Sa-Nguanmoo P, Tanaka Y, Ratanakorn P, Sugiyama M, Murakami S, Payungporn S, Sommanustweechai A, Mizokami M, Poovorawan Y. Cross-species transmission of gibbon and

orangutan hepatitis B virus to uPA/SCID mice with human hepatocytes. *Virus Res.* 2011 Jun;158(1-2):209-15.

26. ○Sugauchi F, Tanaka Y, Kusumoto S, Matsuura K, Sugiyama M, Kurbanov F, Ueda R, Mizokami M. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. *J Med Virol.* 2011 Mar;83(3):412-8.
27. ○Yuen MF, Wong DK, Lee CK, Tanaka Y, Allain JP, Fung J, Leung J, Lin CK, Sugiyama M, Sugauchi F, Mizokami M, Lai CL. Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. *Clin Infect Dis.* 2011 Mar 1;52(5):624-32.
28. ○Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Clinical significance of hepatitis B virus (HBV)-DNA monitoring to detect HBV reactivation after systemic chemotherapy. *J Clin Oncol.* 2011 Feb 1;29(4):e100; author reply e101.
29. ○Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokami M, Kudo M. Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009. *Hepatol Res.* 2011 Jan;41(1):1-21.
30. ○Wu S, Imazeki F, Kurbanov F, Fukai K, Arai M, Kanda T, Yonemitsu Y, Tanaka Y, Mizokami M, Yokosuka O. Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion. *J Hepatol.* 2011 Jan;54(1):19-25.
31. ○Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. *J Gastroenterol.* 2011 Jan;46(1):9-16.
32. ○Ito K, Qin Y, Guarnieri M, Garcia T, Kwei K, Mizokami M, Zhang J, Li J, Wands JR, Tong S. Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. *J Virol.* 2010 Dec;84(24):12850-61.
33. ○Kusakabe A, Tanaka Y, Inoue M, Kurbanov F, Tatematsu K, Nojiri S, Joh T, Tsugane S, Mizokami M. A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan. *J Gastroenterol.* 2011 Jan;46(1):117-24.
34. ○Yoshida T, Kusumoto S, Inagaki A, Mori F, Ito A, Ri M, Ishida T, Komatsu H, Iida S, Sugauchi F, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports. *Int J Hematol.* 2010 Jun;91(5):844-9.
35. ○Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. *Hepatol Res.* 2010 Jan;40(1):14-30.
36. ○Mukaide M, Tanaka Y, Shin-I T, Yuen MF, Kurbanov F, Yokosuka O, Sata M, Karino Y, Yamada G, Sakaguchi K, Orito E, Inoue M, Baqai S, Lai CL, Mizokami M. Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation. *Antimicrob Agents Chemother.* 2010 Feb;54(2):882-9.
37. Yuen M F, Tanaka Y, Fong D Y, Fung J, Wong D K, Yuen J C, But D Y, Chan A O, Wong B C, Mizokami M, Lai C L. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. *J Hepatol* 50 (1):80-8, 2009.
38. Kurahashi N, Inoue M, Iwasaki M, Tanaka Y, Mizokami M, Tsugane S. Vegetable, fruit and antioxidant

nutrient consumption and subsequent risk of hepatocellular carcinoma: a prospective cohort study in Japan. *Br J Cancer* 100 (1):181-4, 2009.

39. Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, Tsugane S. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. *Eur J Cancer Prev* 18 (1):26-32, 2009.
40. Matsuura K, Tanaka Y, Hasegawa I, Ohno T, Tokuda H, Kurbanov F, Sugauchi F, Nojiri S, Joh T, Mizokami M. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. *J Clin Microbiol* 47 (2):385-9, 2009.
41. Sugiyama M, Tanaka Y, Kurbanov F, Maruyama I, Shimada T, Takahashi S, Shirai T, Hino K, Sakaida I, Mizokami M. Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. *Gastroenterology* 136 (2):652-62 e3, 2009.
42. Ikegami T, Matsuki Y, Tanaka Y, Mizokami M, Honda A, Hirayama T, Saito Y, Matsuzaki Y. Impact of determination of hepatitis B virus subgenotype and pre-core/core-promoter mutation for the prediction of acute exacerbation of asymptomatic carriers. *Hepatol Res* 39 (4):341-5, 2009.
43. Kurahashi N, Inoue M, Iwasaki M, Tanaka Y, Mizokami M, Tsugane S. Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population-based prospective cohort of Japanese men and women. *Int J Cancer* 124 (7):1644-9, 2009.
44. Matsuura K, Tanaka Y, Hige S, Yamada G, Murawaki Y, Komatsu M, Kuramitsu T, Kawata S, Tanaka E, Izumi N, Okuse C, Kakumu S, Okanoue T, Hino K, Hiasa Y, Sata M, Maeshiro T, Sugauchi F, Nojiri S, Joh T, Miyakawa Y, Mizokami M. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. *J Clin Microbiol* 47 (5):1476-83, 2009.
45. Elkady A, Tanaka Y, Kurbanov F, Sugauchi F, Sugiyama M, Khan A, Sayed D, Moustafa G, Abdel-Hameed A R, Mizokami M. Genetic variability of hepatitis C virus in South Egypt and its possible clinical implication. *J Med Virol* 81 (6):1015-23, 2009.
46. Inoue M, Kurahashi N, Iwasaki M, Shimazu T, Tanaka Y, Mizokami M, Tsugane S. Effect of coffee and green tea consumption on the risk of liver cancer: cohort analysis by hepatitis virus infection status.
47. Cancer Epidemiol Biomarkers Prev 18 (6):1746-53, 2009.
48. Inoue M, Kurahashi N, Iwasaki M, Tanaka Y, Mizokami M, Noda M, Tsugane S. Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). *Cancer Causes Control* 20 (5):741-50, 2009.
49. Khan A, Tanaka Y, Azam Z, Abbas Z, Kurbanov F, Saleem U, Hamid S, Jafri W, Mizokami M. Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. *J Med Virol* 81 (7):1189-97, 2009.
50. Kusakabe A, Tanaka Y, Mochida S, Nakayama N, Inoue K, Sata M, Isoda N, Kang J H, Sumino Y,

Yatsuhashi H, Takikawa Y, Kaneko S, Yamada G, Karino Y, Tanaka E, Kato J, Sakaida I, Izumi N, Sugauchi F, Nojiri S, Joh T, Miyakawa Y, Mizokami M. Case-control study for the identification of virological factors associated with fulminant hepatitis B. *Hepatol Res* 39 (7):648-56, 2009.

51. Fung J, Lai C L, Tanaka Y, Mizokami M, Yuen J, Wong D K, Yuen M F. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. *Am J Gastroenterol* 104 (8):1940-6; quiz 1947, 2009.
52. Aly H H, Qi Y, Atsuzawa K, Usuda N, Takada Y, Mizokami M, Shimotohno K, Hijikata M. Strain-dependent viral dynamics and virus-cell interactions in a novel in vitro system supporting the life cycle of blood-borne hepatitis C virus. *Hepatology* 50 (3):689-96, 2009.
53. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 41 (10):1105-9, 2009.
54. Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, Nakayoshi T, Wakuta M, Miyakawa Y, Mizokami M. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. *J Virol* 83 (20):10538-47, 2009.
55. Yuen M F, Tanaka Y, Shinkai N, Poon R T, But D Y, Fong D Y, Fung J, Wong D K, Yuen J C, Mizokami M, Lai C L. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. *Gut* 57 (1):98-102, 2008.
56. Avazova D, Kurbanov F, Tanaka Y, Sugiyama M, Radchenko I, Ruziev D, Musabaev E, Mizokami M. Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan. *J Med Virol* 80 (2):217-24, 2008.
57. Khan A, Kurbanov F, Tanaka Y, Elkady A, Sugiyama M, Dustov A, Mizokami M. Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in Tajikistan. *J Med Virol* 80 (2):268-76, 2008.
58. Elkady A, Tanaka Y, Kurbanov F, Oynsuren T, Mizokami M. Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia. *J Gastroenterol Hepatol* 23 (3):474-81, 2008.
59. Khan A, Tanaka Y, Saito H, Ebinuma H, Sekiguchi H, Iwama H, Wakabayashi G, Kamiya T, Kurbanov F, Elkady A, Mizokami M. Transmission of hepatitis B virus (HBV) genotypes among Japanese immigrants and natives in Bolivia. *Virus Res* 132 (1-2):174-80, 2008.
60. Kajiwara E, Tanaka Y, Ohashi T, Uchimura K, Sadoshima S, Kinjo M, Mizokami M. Hepatitis B caused by a hepatitis B surface antigen escape mutant. *J Gastroenterol* 43 (3):243-7, 2008.
61. Kurbanov F, Tanaka Y, Avazova D, Khan A, Sugauchi F, Kan N, Kurbanova-Khudayberganova D, Khikmatullaeva A, Musabaev E, Mizokami M. Detection of hepatitis C virus natural recombinant RF1_2k/1b strain among intravenous drug users in Uzbekistan. *Hepatol Res* 38 (5):457-464, 2008.

62. Ohno T, Tanaka Y, Sugauchi F, Orito E, Hasegawa I, Nukaya H, Kato A, Matunaga S, Endo M, Sakakibara K, Mizokami M. Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis. *Hepatol Res* 38 (7):683-8, 2008.
63. Togashi H, Hashimoto C, Yokozawa J, Suzuki A, Sugahara K, Saito T, Yamaguchi I, Badawi H, Kainuma N, Aoyama M, Ohya H, Akatsuka T, Tanaka Y, Mizokami M, Kawata S. What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? *J Hepatol* 49 (1):17-24, 2008.
64. Wakimoto H, Ogura M, Yano H, Koguchi A, Wakimoto Y, Miyakawa S, Doi M, Okuzumi K, Mizokami M. Pulsed field gel electrophoresis analysis conditions for molecular epidemiological group B streptococcus identification. *Kansenshogaku Zasshi* 82 (4):351-3, 2008.
65. Liu W C, Lindh M, Buti M, Phiet P H, Mizokami M, Li H H, Sun K T, Young K C, Cheng P N, Wu I C, Chang T T. Genotyping of hepatitis B virus--genotypes a to g by multiplex polymerase chain reaction. *Intervirology* 51 (4):247-52, 2008.
66. 136. Fung J, Lai C L, Yuen J C, Wong D K, Tanaka Y, Mizokami M, Yuen M F. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. *Antivir Ther* 12 (1):41-6, 2007.
67. Sanchez L V, Tanaka Y, Maldonado M, Mizokami M, Panduro A. Difference of hepatitis B virus genotype distribution in two groups of mexican patients with different risk factors. High prevalence of genotype H and G. *Intervirology* 50 (1):9-15, 2007.
68. Tanaka Y, Mizokami M. Genetic diversity of hepatitis B virus as an important factor associated with differences in clinical outcomes. *J Infect Dis* 195 (1):1-4, 2007.
69. Zhao H, Kurbanov F, Wan M B, Yin Y K, Niu J Q, Hou J L, Wei L, Wang G Q, Tanaka Y, Mizokami M, Si C W. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. *Clin Infect Dis* 44 (4):541-8, 2007.
70. Kimura Y, Sato K, Tokuda H, Nakamura N, Dohi Y, Orito E, Mizokami M. Effects of combination therapy with direct hemoperfusion using polymyxin B-immobilized fiber and oral vancomycin on fulminant pseudomembranous colitis with septic shock. *Dig Dis Sci* 52 (3):675-8, 2007.
71. Nukaya H, Ohno T, Sakakibara K, Kato A, Hasegawa I, Matunaga S, Endo M, Tanaka Y, Hirashima N, Orito E, Joh T, Mizokami M. Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment. *Hepatol Res* 37 (3):179-85, 2007.
72. Utsumi T, Yano Y, Truong B X, Tanaka Y, Mizokami M, Seo Y, Kasuga M, Kawabata M, Hayashi Y.
73. Molecular epidemiological study of hepatitis B virus infection in two different ethnic populations from the Solomon Islands. *J Med Virol* 79 (3):229-35, 2007.
74. Kusakabe A, Tanaka Y, Orito E, Sugauchi F, Kurbanov F, Sakamoto T, Shinkai N, Hirashima N, Hasegawa I, Ohno T, Ueda R, Mizokami M. A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. *J Gastroenterol* 42 (4):298-305, 2007.
75. Sugiyama M, Tanaka Y, Sakamoto T, Maruyama I, Shimada T, Takahashi S, Shirai T, Kato H, Nagao

M, Miyakawa Y, Mizokami M. Early dynamics of hepatitis B virus in chimeric mice carrying human hepatocytes monoinfected or coinfected with genotype G. *Hepatology* 45 (4):929-37, 2007.

76. Hanada K, Tanaka Y, Mizokami M, Gojobori T, Alter H J. A reduction in selective immune pressure during the course of chronic hepatitis C correlates with diminished biochemical evidence of hepatic inflammation. *Virology* 361 (1):27-33, 2007.
77. Wang Z, Tanaka Y, Huang Y, Kurbanov F, Chen J, Zeng G, Zhou B, Mizokami M, Hou J. Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. *J Clin Microbiol* 45 (5):1491-6, 2007.
78. Kato H, Maeno Y, Seko-Nakamura Y, Monma-Ohtaki J, Sugiura S, Takahashi K, Zhe L X, Matsumoto T, Kurvanov F, Mizokami M, Nagao M. Identification and phylogenetic analysis of hepatitis C virus in forensic blood samples obtained from injecting drug users. *Forensic Sci Int* 168 (1):27-33, 2007.
79. Date T, Miyamoto M, Kato T, Morikawa K, Murayama A, Akazawa D, Tanabe J, Sone S, Mizokami M, Wakita T. An infectious and selectable full-length replicon system with hepatitis C virus JFH-1 strain. *Hepatol Res* 37 (6):433-43, 2007.
80. Wang Z, Hou J, Zeng G, Wen S, Tanaka Y, Cheng J, Kurbanov F, Wang L, Jiang J, Naoumov N V, Mizokami M, Qi Y. Distribution and characteristics of hepatitis B virus genotype C subgenotypes in China. *J Viral Hepat* 14 (6):426-34, 2007.
81. Yuan J, Zhou B, Tanaka Y, Kurbanov F, Orito E, Gong Z, Xu L, Lu J, Jiang X, Lai W, Mizokami M. Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications. *J Clin Virol* 39 (2):87-93, 2007.
82. Lok A S, Zoulim F, Locarnini S, Bartholomeusz A, Ghany M G, Pawlotsky J M, Liaw Y F, Mizokami M, Kuiken C. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. *Hepatology* 46 (1):254-65, 2007.
83. Orito E, Mizokami M. Differences of HBV genotypes and hepatocellular carcinoma in Asian countries.Hepatol Res 37 (s1):S33-5, 2007.
84. Tajiri H, Tanaka Y, Kagimoto S, Murakami J, Tokuhara D, Mizokami M. Molecular evidence of father-to-child transmission of hepatitis B virus. *J Med Virol* 79 (7):922-6, 2007.
85. Murayama A, Date T, Morikawa K, Akazawa D, Miyamoto M, Kaga M, Ishii K, Suzuki T, Kato T, Mizokami M, Wakita T. The NS3 helicase and NS5B-to-3'X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells. *J Virol* 81 (15):8030-40, 2007.
86. Kurbanov F, Tanaka Y, Elkady A, Oyunsuren T, Mizokami M. Tracing hepatitis C and Delta viruses to estimate their contribution in HCC rates in Mongolia. *J Viral Hepat* 14 (9):667-74, 2007.
87. Kusakabe A, Tanaka Y, Kurbanov F, Goto K, Tajiri H, Murakami J, Okuse C, Yotsuyanagi H, Joh T, Mizokami M. Virological features of hepatitis B virus-associated nephropathy in Japan. *J Med Virol* 79 (9):1305-11, 2007.
88. Tanaka Y, Hanada K, Hanabusa H, Kurbanov F, Gojobori T, Mizokami M. Increasing genetic diversity of hepatitis C virus in haemophiliacs with human immunodeficiency virus coinfection. *J Gen Virol* 88 (Pt 9):2513-9, 2007.

89. Truong B X, Yano Y, Seo Y, Phuong T M, Tanaka Y, Kato H, Miki A, Utsumi T, Azuma T, Trach N K, Mizokami M, Hayashi Y, Kasuga M. Variations in the core promoter/pre-core region in HBV genotype C in Japanese and Northern Vietnamese patients. *J Med Virol* 79 (9):1293-304, 2007.
90. Sugiyama M, Tanaka Y, Kurbanov F, Nakayama N, Mochida S, Mizokami M. Influences on hepatitis B virus replication by a naturally occurring mutation in the core gene. *Virology* 365 (2):285-91, 2007.
91. Maeshiro T, Arakaki S, Watanabe T, Aoyama H, Shiroma J, Yamashiro T, Hirata T, Hokama A, Kinjo F, Nakayoshi T, Mizokami M, Fujita J, Sakugawa H. Different natural courses of chronic hepatitis B with genotypes B and C after the fourth decade of life. *World J Gastroenterol* 13 (34):4560-5, 2007.
92. Ito K, Tanaka Y, Kato M, Fujiwara K, Sugauchi F, Sakamoto T, Shinkai N, Orito E, Mizokami M. Comparison of complete sequences of hepatitis B virus genotype C between inactive carriers and hepatocellular carcinoma patients before and after seroconversion. *J Gastroenterol* 42 (10):837-44, 2007.
93. Shinkai N, Tanaka Y, Ito K, Mukaide M, Hasegawa I, Asahina Y, Izumi N, Yatsuhashi H, Orito E, Joh T, Mizokami M. Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. *J Clin Microbiol* 45 (10):3191-7, 2007.
94. Elkady A, Tanaka Y, Kurbanov F, Hirashima N, Sugiyama M, Khan A, Kato H, Okumura A, Mizokami M. Evaluation of anti-hepatitis E virus (HEV) immunoglobulin A in a serological screening for HEV infection. *J Gastroenterol* 42 (11):911-7, 2007.
95. Sakamoto T, Tanaka Y, Simonetti J, Osiowy C, Borresen M L, Koch A, Kurbanov F, Sugiyama M, Minuk G Y, McMahon B J, Joh T, Mizokami M. Classification of hepatitis B virus genotype B into 2 major types based on characterization of a novel subgenotype in Arctic indigenous populations. **J Infect Dis** 196 (10):1487-92, 2007.
96. Wong D K, Tanaka Y, Lai C L, Mizokami M, Fung J, Yuen M F. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. **J Clin Microbiol** 45 (12):3942-7, 2007.
97. Yano Y, Truong B X, Seo Y, Kato H, Miki A, Tanaka Y, Mizokami M, Kagawa A, Miyazaki H, Kasuga M, Azuma T, Hayashi Y. Japanese case of hepatitis B virus genotypes C/D hybrid. *Hepatol Res* 37 (12):1095-9, 2007.
98. Mizokami M, Tanaka Y, Miyakawa Y. Spread times of hepatitis C virus estimated by the molecular clock differ among Japan, the United States and Egypt in reflection of their distinct socioeconomic backgrounds. *Intervirology* 49 (1-2):28-36, 2006.
99. Michitaka K, Tanaka Y, Horiike N, Duong T N, Chen Y, Matsuura K, Hiasa Y, Mizokami M, Onji M. Tracing the history of hepatitis B virus genotype D in western Japan. J Med Virol 78 (1):44-52, 2006.
100. Ito K, Tanaka Y, Orito E, Sugiyama M, Fujiwara K, Sugauchi F, Kato T, Tokita H, Izumi N, Kato M, Yuen M F, Lai C L, Gish R G, Ueda R, Mizokami M. T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. Clin Infect Dis 42 (1):1-7, 2006.
101. Tanaka E, Matsumoto A, Suzuki F, Kobayashi M, Mizokami M, Tanaka Y, Okanoue T, Minami M, Chayama K, Imamura M, Yatsuhashi H, Nagaoka S, Yotsuyanagi H, Kawata S, Kimura T, Maki N, Iino

S, Kiyosawa K. Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. Liver Int 26 (1):90-6, 2006.

102. Tanaka Y, Kurbanov F, Mano S, Orito E, Vargas V, Esteban J I, Yuen M F, Lai C L, Kramvis A, Kew M C, Smuts H E, Netesov S V, Alter H J, Mizokami M.

103. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 130 (3):703-14, 2006.

104. Yuan J, Zhou B P, Gong Z J, Xu L M, Jiang X L, Mizokami M. [Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 20 (1):30-2, 2006.

105. Tanaka Y, Takahashi K, Orito E, Karino Y, Kang J H, Suzuki K, Matsui A, Hori A, Matsuda H, Sakugawa H, Asahina Y, Kitamura T, Mizokami M, Mishiro S. Molecular tracing of Japan-indigenous hepatitis E viruses. J Gen Virol 87 (Pt 4):949-54, 2006.

106. Kuiken C, Mizokami M, Deleage G, Yusim K, Penin F, Shin I T, Charavay C, Tao N, Crisan D, Grando D, Dalwani A, Geourjon C, Agrawal A, Combet C. Hepatitis C databases, principles and utility to researchers. Hepatology 43 (5):1157-65, 2006.

107. Agha S, El-Mashad N, El-Malky M, El-Shony H, El-Sherif M Z, El-Hasan M A, Tanaka Y, Mizokami M. Prevalence of low positive anti-HCV antibodies in blood donors: Schistosoma mansoni co-infection and possible role of autoantibodies. Microbiol Immunol 50 (6):447-52, 2006.

108. Orito E, Fujiwara K, Tanaka Y, Yuen M F, Lai C L, Kato T, Sugauchi F, Kusakabe A, Sata M, Okanoue T, Niitsuma H, Sakugawa H, Hasegawa I, Mizokami M. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Hepatol Res 35 (2):127-34, 2006.

109. Sakamoto T, Tanaka Y, Orito E, Co J, Clavio J, Sugauchi F, Ito K, Ozasa A, Quino A, Ueda R, Sollano J, Mizokami M. Novel subtypes (subgenotypes) of hepatitis B virus genotypes B and C among chronic liver disease patients in the Philippines. J Gen Virol 87 (Pt 7):1873-82, 2006.

110. Hasegawa I, Tanaka Y, Kurbanov F, Yoshihara N, El-Gohary A, Lyamuya E, Matee M, Magessa P, Fujiwara K, Ozasa A, Sugauchi F, Orito E, Ueda R, Mizokami M. Molecular epidemiology of hepatitis B virus in the United Republic of Tanzania. J Med Virol 78 (8):1035-42, 2006.

111. Ozasa A, Tanaka Y, Orito E, Sugiyama M, Kang J H, Hige S, Kuramitsu T, Suzuki K, Tanaka E, Okada S, Tokita H, Asahina Y, Inoue K, Kakumu S, Okanoue T, Murawaki Y, Hino K, Onji M, Yatsuhashi H, Sakugawa H, Miyakawa Y, Ueda R, Mizokami M. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 44 (2):326-34, 2006.

112. Sugihara K, Orito E, Tanaka Y, Kato T, Lau J Y, Ohno T, Hayashi K, Ogino M, Hirashima N, Sakakibara K, Mizuno Y, Kato H, Suzuki S, Ueda R, Mizokami M. Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy. Intervirology 49 (6):319-26, 2006.

113. Banerjee A, Kurbanov F, Datta S, Chandra P K, Tanaka Y, Mizokami M, Chakravarty R. Phylogenetic

relatedness and genetic diversity of hepatitis B virus isolates in Eastern India. J Med Virol 78 (9):1164-74, 2006.

114. Sugauchi F, Orito E, Ohno T, Tanaka Y, Ozasa A, Kang J H, Toyoda J, Kuramitsu T, Suzuki K, Tanaka E, Akahane Y, Ichida T, Izumi N, Inoue K, Hoshino H, Iino S, Yotsuyanagi H, Kakumu S, Tomita E, Okanoue T, Nishiguchi S, Murawaki Y, Hino K, Onji M, Yatsuhashi H, Sata M, Miyakawa Y, Ueda R, Mizokami M. Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res 36 (2):107-114, 2006.

115. Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya S K, Gish R G, Kramvis A, Shimada T, Izumi N, Kaito M, Miyakawa Y, Mizokami M. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 44 (4):915-24, 2006.

116. Kuiken C, Combet C, Bukh J, Shin I T, Deleage G, Mizokami M, Richardson R, Sablon E, Yusim K, Pawlotsky J M, Simmonds P. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology 44 (5):1355-61, 2006.

117. Osiowy C, Giles E, Tanaka Y, Mizokami M, Minuk G Y. Molecular evolution of hepatitis B virus over 25 years. J Virol 80 (21):10307-14, 2006.

118. Tanaka Y, Mukaide M, Orito E, Yuen M F, Ito K, Kurbanov F, Sugauchi F, Asahina Y, Izumi N, Kato M, Lai C L, Ueda R, Mizokami M. Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol 45 (5):646-53, 2006.

119. Oyunsuren T, Kurbanov F, Tanaka Y, Elkady A, Sanduijav R, Khajidsuren O, Dagvadorj B, Mizokami M. High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses. J Med Virol 78 (12):1688-95, 2006.

120. Shinkai N, Tanaka Y, Orito E, Ito K, Ohno T, Hirashima N, Hasegawa I, Sugauchi F, Ueda R, Mizokami M. Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res 36 (4):272-276, 2006.

121. Liu W C, Mizokami M, Buti M, Lindh M, Young K C, Sun K T, Chi Y C, Li H H, Chang T T. Simultaneous quantification and genotyping of hepatitis B virus for genotypes A to G by real-time PCR and two-step melting curve analysis. J Clin Microbiol 44 (12):4491-7, 2006.

122. Kato H, Nakamura M, Orito E, Ueda R, Tsuzuki T, Mizokami M. A case of gastrointestinal stromal tumor with internal tandem duplication in the 3'-terminal of the KIT juxtamembrane domain. Dig Dis Sci 50 (1):70-7, 2005.

123. Kato T, Date T, Miyamoto M, Zhao Z, Mizokami M, Wakita T. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol 79 (1):592-6, 2005.

124. Ogata K, Ide T, Kumashiro R, Kumada H, Yotsuyanagi H, Okita K, Akahane Y, Kaneko S, Tsubouchi H, Tanaka E, Moriwaki H, Nishiguchi S, Kakumu S, Mizokami M, Iino S, Sata M. Timing of interferon therapy and sources of infection in patients with acute hepatitis C. Hepatol Res 34 (1):35-40, 2006.

125. Tanaka Y, Hanada K, Orito E, Akahane Y, Chayama K, Yoshizawa H, Sata M, Ohta N, Miyakawa Y, Gojobori T, Mizokami M. Molecular evolutionary analyses implicate injection treatment for

schistosomiasis in the initial hepatitis C epidemics in Japan. J Hepatol 42 (1):47-53, 2005.

126.Mukaide M, Tanaka Y, Kakuda H, Fujiwara K, Kurbanov F, Orito E, Yoshioka K, Fujise K, Harada S, Kozaki T, Takemura K, Hikiji K, Mizokami M. New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0. World J Gastroenterol 11 (4):469-75, 2005.

127.Iino S, Tomita E, Kumada H, Suzuki H, Toyota J, Kiyosawa K, Tanikawa K, Sata M, Hayashi N, Kakumu S, Matsushima T, Mizokami M. Impact of daily high-dose IFNalpha-2b plus ribavirin combination therapy on reduction of ALT levels in patients with chronic hepatitis C with genotype 1 and high HCV RNA levels. Hepatol Res 31 (2):88-94, 2005.

128.Hasegawa I, Orito E, Tanaka Y, Hirashima N, Sakakibara K, Sakurai M, Suzuki S, Sugauchi F, Ohno T, Ueda R, Mizokami M. Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver Int 25 (2):247-53, 2005.

129.Kusakabe A, Kato H, Hayashi K, Igami T, Hasegawa H, Tsuzuki T, Ueda R, Mizokami M. Pyogenic granuloma of the stomach successfully treated by endoscopic resection after transarterial embolization of the feeding artery. J Gastroenterol 40 (5):530-5, 2005.

130.Kurbanov F, Tanaka Y, Fujiwara K, Sugauchi F, Mbanya D, Zekeng L, Ndembi N, Ngansop C, Kaptue L, Miura T, Ido E, Hayami M, Ichimura H, Mizokami M. A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. J Gen Virol 86 (Pt 7):2047-56, 2005.

131.Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich H G, Mizokami M, Bartenschlager R, Liang T J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 (7):791-6, 2005.

132.Orito E, Sugauchi F, Tanaka Y, Ichida T, Sata M, Tanaka E, Okanoue T, Sakugawa H, Watanabe H, Miyakawa H, Nishiguchi S, Kumada H, Ueda R, Mizokami M. Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in Japan. Intervirology 48 (4):239-45, 2005.

133.Wakimoto H, Yano H, Baba S, Okuzumi K, Okamoto N, Wakimoto Y, Miyakawa S, Mizokami M. Pulsed field gel electrophoresis analysis conditions for molecular epidemiological identification of vertical Group B Streptococcus infection. Kansenshogaku Zasshi 79 (8):561-3, 2005.

134.脇本寛子, 矢野久子, 馬場重好, 奥住捷子, 岡本典子, 脇本幸夫, 宮川創平, 溝上雅史. Pulsed Field Gel Electrophoresis Analysis Conditions for Molecular Epidemiological Identification of Vertical Group B Streptococcus Infection. 感染症学雑誌 79 (8):561-563, 2005.

135.Miyamoto M, Kato T, Date T, Mizokami M, Wakita T. Comparison between subgenomic replicons of hepatitis C virus genotypes 2a (JFH-1) and 1b (Con1 NK5.1). Intervirology 49 (1-2):37-43, 2006.

136.Yuen M F, Tanaka Y, Ng I O, Mizokami M, Yuen J C, Wong D K, Yuan H J, Sum S M, Chan A O, Lai C L. Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations. J Viral Hepat 12 (5):513-8, 2005.

137.Bae S H, Yoon S K, Jang J W, Kim C W, Nam S W, Choi J Y, Kim B S, Park Y M, Suzuki S, Sugauchi F, Mizokami M. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J

Korean Med Sci 20 (5):816-20, 2005.

138. Banno S, Ito Y, Tanaka C, Hori T, Fujimoto K, Suzuki T, Hashimoto T, Ueda R, Mizokami M. Quantification of red blood cell fragmentation by the automated hematology analyzer XE-2100 in patients with living donor liver transplantation. Clin Lab Haematol 27 (5):292-6, 2005.

139. Mizokami M, Tanaka Y. Tracing the evolution of hepatitis C virus in the United States, Japan, and Egypt by using the molecular clock. Clin Gastroenterol Hepatol 3 (10 Suppl 2):S82-5, 2005.

140. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy D G, Okamoto H, Pawlotsky J M, Penin F, Sablon E, Shin I T, Stuyver L J, Thiel H J, Viazov S, Weiner A J, Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42 (4):962-73, 2005.

141. Kato H, Fujiwara K, Gish R G, Sakugawa H, Yoshizawa H, Sugauchi F, Orito E, Ueda R, Tanaka Y, Kato T, Miyakawa Y, Mizokami M. Classifying genotype F of hepatitis B virus into F1 and F2 subtypes. World J Gastroenterol 11 (40):6295-304, 2005.

142. Fujiwara K, Tanaka Y, Paulon E, Orito E, Sugiyama M, Ito K, Ueda R, Mizokami M, Naoumov N V. Novel type of hepatitis B virus mutation: replacement mutation involving a hepatocyte nuclear factor 1 binding site tandem repeat in chronic hepatitis B virus genotype E. J Virol 79 (22):14404-10, 2005.

143. Kato T, Date T, Miyamoto M, Sugiyama M, Tanaka Y, Orito E, Ohno T, Sugihara K, Hasegawa I, Fujiwara K, Ito K, Ozasa A, Mizokami M, Wakita T. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol 43 (11):5679-84, 2005.

144. Tanaka Y, Orito E, Yuen M F, Mukaide M, Sugauchi F, Ito K, Ozasa A, Sakamoto T, Kurbanov F, Lai C L, Mizokami M. Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism. Hepatol Res 33 (3):216-24, 2005.

145. Fujiwara K, Tanaka Y, Orito E, Ohno T, Kato T, Sugihara K, Hasegawa I, Sakurai M, Ito K, Ozasa A, Sakamoto Y, Arita I, El-Gohary A, Benoit A, Ogoundele-Akplogan S I, Yoshihara N, Ueda R, Mizokami M. Distribution of HBV genotypes among HBV carriers in Benin:phylogenetic analysis and virological characteristics of HBV genotype E. World J Gastroenterol 11 (41):6410-5, 2005.

146. Tanaka Y, Agha S, Saudy N, Kurbanov F, Orito E, Kato T, Abo-Zeid M, Khalaf M, Miyakawa Y, Mizokami M. Exponential spread of hepatitis C virus genotype 4a in Egypt. J Mol Evol 58 (2):191-5, 2004.

147. Ito K, Tanaka Y, Orito E, Hirashima N, Ide T, Hino T, Kumashiro R, Kato A, Nukaya H, Sakakibara K, Mukaide M, Ito H, Sata M, Ueda R, Mizokami M. Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection. Clin Infect Dis 38 (4):490-5, 2004.

148. Duong T N, Horiike N, Michitaka K, Yan C, Mizokami M, Tanaka Y, Jyoko K, Yamamoto K, Miyaoka H, Yamashita Y, Ohno N, Onji M. Comparison of genotypes C and D of the hepatitis B virus in Japan: a clinical and molecular biological study. J Med Virol 72 (4):551-7, 2004.

149. Sugauchi F, Kumada H, Acharya S A, Shrestha S M, Gamutan M T, Khan M, Gish R G, Tanaka Y, Kato T, Orito E, Ueda R, Miyakawa Y, Mizokami M. Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. J Gen Virol 85 (Pt 4):811-20, 2004.

150.Hirashima N, Orito E, Ohba K, Kondo H, Sakamoto T, Matsunaga S, Kato A, Nukaya H, Sakakibara K, Ohno T, Kato H, Sugauchi F, Kato T, Tanaka Y, Ueda R, Mizokami M. A randomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype 1b and high viral load. Hepatol Res 29 (1):9-12, 2004.

151.Tanaka Y, Pfeiffer R, Yeo A E, Mizokami M, Edlin B R, Castle P, O'Brien T R, Alter H J, Shih J W. PCR-probe capture hybridization assay and statistical model for SEN virus prevalence estimation. J Med Virol 73 (1):123-30, 2004.

152.Sugauchi F, Kumada H, Sakugawa H, Komatsu M, Niitsuma H, Watanabe H, Akahane Y, Tokita H, Kato T, Tanaka Y, Orito E, Ueda R, Miyakawa Y, Mizokami M. Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan. Clin Infect Dis 38 (9):1222-8, 2004.

153.Date T, Kato T, Miyamoto M, Zhao Z, Yasui K, Mizokami M, Wakita T. Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J Biol Chem 279 (21):22371-6, 2004.

154.Agha S, Tanaka Y, Saudy N, Kurbanov F, Abo-Zeid M, El-Malky M, Khalaf M, Ohta N, Yoshizawa H, Mizokami M. Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: a collaborative study between Japan, Egypt, and Uzbekistan. J Med Virol 73 (2):216-22, 2004.

155.Kato H, Nakamura M, Ito T, Ito Y, Orito E, Ueda R, Tsuzuki T, Mizokami M. Enterovesical fistula complication in B-cell-type lymphoma of the small intestine. J Gastroenterol 39 (6):589-91, 2004.

156.Shinji T, Kyaw Y Y, Gokan K, Tanaka Y, Ochi K, Kusano N, Mizushima T, Fujioka S, Shiraha H, Lwin A A, Shiratori Y, Mizokami M, Khin M, Miyahara M, Okada S, Koide N. Analysis of HCV genotypes from blood donors shows three new HCV type 6 subgroups exist in Myanmar. Acta Med Okayama 58 (3):135-42, 2004.

157.Hasegawa I, Tanaka Y, Kramvis A, Kato T, Sugauchi F, Acharya S K, Orito E, Ueda R, Kew M C, Mizokami M. Novel hepatitis B virus genotype a subtyping assay that distinguishes subtype Aa from Ae and its application in epidemiological studies. J Virol 78 (14):7575-81, 2004.

158.Kato H, Nakamura M, Muramatsu M, Orito E, Ueda R, Mizokami M. Spontaneous regression of hepatocellular carcinoma: two case reports and a literature review. Hepatol Res 29 (3):180-190, 2004.

159.Yamauchi N, Itoh Y, Tanaka Y, Mizokami M, Minami M, Morita A, Toyama T, Yamaguchi K, Fujii H, Okanoue T. Clinical characteristics and prevalence of GB virus C, SEN virus, and HFE gene mutation in Japanese patients with nonalcoholic steatohepatitis. J Gastroenterol 39 (7):654-60, 2004.

160.Yuen M F, Sablon E, Tanaka Y, Kato T, Mizokami M, Doutreloigne J, Yuan H J, Wong D K, Sum S M, Lai C L. Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. J Hepatol 41 (1):119-25, 2004.

161.Kato H, Gish R G, Bzowej N, Newsom M, Sugauchi F, Tanaka Y, Kato T, Orito E, Usuda S, Ueda R, Miyakawa Y, Mizokami M. Eight genotypes (A-H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics. J Med Virol 73 (4):516-21, 2004.

162.Michitaka K, Horiike N, Chen Y, Duong T N, Konishi I, Mashiba T, Tokumoto Y, Hiasa Y, Tanaka Y,

Mizokami M, Onji M. Gianotti-Crosti syndrome caused by acute hepatitis B virus genotype D infection.Intern Med 43 (8):696-9, 2004.

163.Tanaka Y, Yeo A E, Orito E, Ito K, Hirashima N, Ide T, Sata M, Mizokami M. Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for chronic hepatitis B virus infection. J Gastroenterol 39 (8):769-75, 2004.

164.Sakurai M, Sugauchi F, Tsai N, Suzuki S, Hasegawa I, Fujiwara K, Orito E, Ueda R, Mizokami M. Genotype and phylogenetic characterization of hepatitis B virus among multi-ethnic cohort in Hawaii. World J Gastroenterol 10 (15):2218-22, 2004.

165.Mizokami M, Tanaka Y. Molecular evolutionary analysis predicts the incidence of hepatocellular carcinoma in the United States and Japan. Cancer Chemother Pharmacol 54 Suppl 1:S83-6, 2004.

166.Tanaka Y, Hasegawa I, Kato T, Orito E, Hirashima N, Acharya S K, Gish R G, Kramvis A, Kew M C, Yoshihara N, Shrestha S M, Khan M, Miyakawa Y, Mizokami M. A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology 40 (3):747-55, 2004.

167.Yuen M F, Tanaka Y, Mizokami M, Yuen J C, Wong D K, Yuan H J, Sum S M, Chan A O, Wong B C, Lai C L. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogenesis 25 (9):1593-8, 2004.

168.Satoh Y, Hino K, Kato T, Mizokami M, Yamashita S, Nakamura H, Okita K. Molecular epidemiologic analysis of hepatitis C virus infection in injecting drug users with acute hepatitis C in Japan. J Gastroenterol Hepatol 19 (11):1305-11, 2004.

169.Yuen M F, Fung S K, Tanaka Y, Kato T, Mizokami M, Yuen J C, Wong D K, Yuan H J, Sum S M, Chan A O, Wong B C, Lai C L. Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C. J Clin Microbiol 42 (11):5036-40, 2004.

170.Fujiwara K, Tanaka Y, Orito E, Ohno T, Kato T, Sugauchi F, Suzuki S, Hattori Y, Sakurai M, Hasegawa I, Ozasa T, Kanie F, Kano H, Ueda R, Mizokami M. Lack of association between occult hepatitis B virus DNA viral load and aminotransferase levels in patients with hepatitis C virus-related chronic liver disease. J Gastroenterol Hepatol 19 (12):1343-7, 2004.

171.Kato H, Sugauchi F, Ozasa A, Kato T, Tanaka Y, Sakugawa H, Sata M, Hino K, Onji M, Okanoue T, Tanaka E, Kawata S, Suzuki K, Hige S, Ohno T, Orito E, Ueda R, Mizokami M. Hepatitis B virus genotype G is an extremely rare genotype in Japan. Hepatol Res 30 (4):199-203, 2004.

172.Kato T, Miyamoto M, Date T, Furusaka A, Hiramoto J, Nagayama K, Tsai N, Mizokami M, Wakita T. Differences in hepatitis C virus core protein processing among genotypes 1 and 2. Hepatol Res 30 (4):204-209, 2004.

173.Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 46 (6):329-38, 2003.

174.Orito E, Mizokami M. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Intervirology 46 (6):408-12, 2003.

175.Sugauchi F, Orito E, Kato H, Suzuki S, Kawakita S, Sakamoto Y, Fukushima K, Akiba T, Yoshihara N,

Ueda R, Mizokami M. Genotype, serotype, and phylogenetic characterization of the complete genome sequence of hepatitis B virus isolates from Malawian chronic carriers of the virus. J Med Virol 69 (1):33-40, 2003.

176.Tanaka Y, Furuta T, Suzuki S, Orito E, Yeo A E, Hirashima N, Sugauchi F, Ueda R, Mizokami M. Impact of interleukin-1beta genetic polymorphisms on the development of hepatitis C virus-related hepatocellular carcinoma in Japan. J Infect Dis 187 (11):1822-5, 2003.

177.Kurbanov F, Tanaka Y, Sugauchi F, Kato H, Ruzibakiev R, Zalyalieva M, Yunusova Z, Mizokami M. Hepatitis C virus molecular epidemiology in Uzbekistan. J Med Virol 69 (3):367-75, 2003.

178.Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai C L, Gish R G, Ueda R, Miyakawa Y, Mizokami M. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 124 (4):925-32, 2003.

179.Suzuki S, Sugauchi F, Orito E, Kato H, Usuda S, Siransy L, Arita I, Sakamoto Y, Yoshihara N, El-Gohary A, Ueda R, Mizokami M. Distribution of hepatitis B virus (HBV) genotypes among HBV carriers in the Cote d'Ivoire: complete genome sequence and phylogenetic relatedness of HBV genotype E. J Med Virol 69 (4):459-65, 2003.

180.Kato H, Orito E, Yoshinouchi T, Ueda R, Koizumi T, Yoshinouchi M, Mizokami M. Regression of esophageal papillomatous polyposis caused by high-risk type human papilloma virus. J Gastroenterol 38 (6):579-83, 2003.

181.Kato H, Orito E, Sugauchi F, Ueda R, Koshizaka T, Yanaka S, Gish R G, Kurbanov F, Ruzibakiev R, Kramvis A, Kew M C, Ahmad N, Khan M, Usuda S, Miyakawa Y, Mizokami M. Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. J Virol Methods 110 (1):29-35, 2003.

182.Kato H, Nakamura M, Orito E, Ueda R, Mizokami M. The first report of successful nasogastric Coca-Cola lavage treatment for bitter persimmon phytobezoars in Japan. Am J Gastroenterol 98 (7):1662-3, 2003.

183.Nakayoshi T, Maeshiro T, Nakasone H, Sakugawa H, Kinjo F, Orito E, Mizokami M. Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands: a prospective study. J Med Virol 70 (3):350-4, 2003.

184.Saudy N, Sugauchi F, Tanaka Y, Suzuki S, Aal A A, Zaid M A, Agha S, Mizokami M. Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt. J Med Virol 70 (4):529-36, 2003.

185.Sugauchi F, Ohno T, Orito E, Sakugawa H, Ichida T, Komatsu M, Kuramitsu T, Ueda R, Miyakawa Y, Mizokami M. Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. J Med Virol 70 (4):537-44, 2003.

186.Tanaka Y, Takagi K, Fujihara T, Kitsugi K, Fujiwara K, Hiramatsu K, Ito Y, Takasaka Y, Sakai M, Mizokami M. High stability of enzyme immunoassay for hepatitis C virus core antigen-evaluation before and after incubation at room temperature. Hepatol Res 26 (4):261-267, 2003.

187.Kubo N, Furusyo N, Sawayama Y, Otaguro S, Nabeshima S, Sugauchi F, Mizokami M, Kashiwagi S,

Hayashi J. A patient in whom only hepatitis B virus (HBV) was thought to have been contracted, by kissing, from a same-sex partner coinfected with HBV and human immunodeficiency virus-1. J Infect Chemother 9 (3):260-4, 2003.

188. Kurbanov F, Kondo M, Tanaka Y, Zalalieva M, Giasova G, Shima T, Jounai N, Yuldasheva N, Ruzibakiev R, Mizokami M, Imai M. Human immunodeficiency virus in Uzbekistan: epidemiological and genetic analyses. AIDS Res Hum Retroviruses 19 (9):731-8, 2003.

189. Hattori Y, Orito E, Ohno T, Sugauchi F, Suzuki S, Sugiura M, Suzumori K, Hattori K, Ueda R, Mizokami M. Loss of hepatitis C virus RNA after parturition in female patients with chronic HCV infection. J Med Virol 71 (2):205-11, 2003.

190. Suzuki S, Tanaka Y, Orito E, Sugauchi F, Hasegawa I, Sakurai M, Fujiwara K, Ohno T, Ueda R, Mizokami M. Transforming growth factor-beta-1 genetic polymorphism in Japanese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 18 (10):1139-43, 2003.

191. Mukaide M, Tanaka Y, Katayose S, Tano H, Murata M, Hikata M, Fujise K, Sakugawa H, Suzuki K, Zaunders J, Nagasawa Y, Toda G, Mizokami M. Development of real-time detection direct test for hepatitis B virus and comparison with two commercial tests using the WHO international standard. J Gastroenterol Hepatol 18 (11):1264-71, 2003.

192. Yuen M F, Kato T, Mizokami M, Chan A O, Yuen J C, Yuan H J, Wong D K, Sum S M, Ng I O, Fan S T, Lai C L. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 39 (5):850-5, 2003.

193. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125 (6):1808-17, 2003.

194. Suzuki S, Kondo Y, Hirashima N, Kato H, Sugauchi F, Tanaka Y, Orito E, Yang Y, Shen Y, Sakakibara K, Ueda R, Mizokami M. Evaluation of loss of heterozygosity before and after interferon therapy in patients with hepatitis C virus infection who developed hepatocellular carcinoma during follow up. J Gastroenterol Hepatol 18 (12):1364-72, 2003.

195. Sugauchi F, Orito E, Ohno T, Kato H, Suzuki T, Hashimoto T, Manabe T, Ueda R, Mizokami M. Liver transplantation-associated de novo hepatitis B virus infection: application of molecular evolutionary analysis. Intervirology 45 (1):6-10, 2002.

196. Ding X, Mizokami M, Ge X, Orito E, Iino S, Ueda R, Nakanishi M. Different hepatitis B virus genotype distributions among asymptomatic carriers and patients with liver diseases in Nanning, southern China. Hepatol Res 22 (1):37-44, 2002.

197. Kato H, Orito E, Gish R G, Bzowej N, Newsom M, Sugauchi F, Suzuki S, Ueda R, Miyakawa Y, Mizokami M. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology 35 (4):922-9, 2002.

198. Yamaoka Y, Orito E, Mizokami M, Gutierrez O, Saitou N, Kodama T, Osato M S, Kim J G, Ramirez F C, Mahachai V, Graham D Y. Helicobacter pylori in North and South America before Columbus.

199. FEBS Lett 517 (1-3):180-4, 2002.

200. Pereira L M, Spinelli V, Ximenes R A, Cavalcanti M S, Melo R, Juca N, Mizokami M, McFarlane I G.

Chronic hepatitis C infection: influence of the viral load, genotypes, and GBV-C/HGV coinfection on the severity of the disease in a Brazilian population. J Med Virol 67 (1):27-32, 2002.

201. Kato H, Orito E, Gish R G, Sugauchi F, Suzuki S, Ueda R, Miyakawa Y, Mizokami M. Characteristics of hepatitis B virus isolates of genotype G and their phylogenetic differences from the other six genotypes (A through F). J Virol 76 (12):6131-7, 2002.

202. Sugauchi F, Chutaputti A, Orito E, Kato H, Suzuki S, Ueda R, Mizokami M. Hepatitis B virus genotypes and clinical manifestation among hepatitis B carriers in Thailand. J Gastroenterol Hepatol 17 (6):671-6, 2002.

203. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai C L, Ueda R, Miyakawa Y, Mizokami M. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 76 (12):5985-92, 2002.

204. Kato H, Ruzibakiev R, Yuldasheva N, Hegay T, Kurbanov F, Achundjanov B, Tuichiev L, Usuda S, Ueda R, Mizokami M. Hepatitis B virus genotypes in Uzbekistan and validity of two different systems for genotyping. J Med Virol 67 (4):477-83, 2002.

205. Sakugawa H, Nakasone H, Nakayoshi T, Orito E, Mizokami M, Yamashiro T, Maeshiro T, Kinjo F, Saito A, Miyagi Y. Preponderance of hepatitis B virus genotype B contributes to a better prognosis of chronic HBV infection in Okinawa, Japan. J Med Virol 67 (4):484-9, 2002.

206. Yu S Z, Huang X E, Koide T, Cheng G, Chen G C, Harada K, Ueno Y, Sueoka E, Oda H, Tashiro F, Mizokami M, Ohno T, Xiang J, Tokudome S. Hepatitis B and C viruses infection, lifestyle and genetic polymorphisms as risk factors for hepatocellular carcinoma in Haimen, China. Jpn J Cancer Res 93 (12):1287-92, 2002.

207. Tanaka Y, Hanada K, Mizokami M, Yeo A E, Shih J W, Gojobori T, Alter H J. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A 99 (24):15584-9, 2002.

208. Ding X, Mizokami M, Yao G, Xu B, Orito E, Ueda R, Nakanishi M. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China. Intervirology 44 (1):43-7, 2001.

209. Ruzibakiev R, Kato H, Ueda R, Yuldasheva N, Hegay T, Avazova D, Kurbanov F, Zalalieva M, Tuichiev L, Achundjanov B, Mizokami M. Risk factors and seroprevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection in Uzbekistan. Intervirology 44 (6):327-32, 2001.

210. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 33 (1):218-23, 2001.

211. Isaka M, Yasuda Y, Mizokami M, Kozuka S, Taniguchi T, Matano K, Maeyama J, Mizuno K, Morokuma K, Ohkuma K, Goto N, Tochikubo K. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. Vaccine 19 (11-12):1460-6, 2001.